You are here: Urology Textbook > Drugs in Urology > PDE5 inhibitors > Tadalafil
Tadalafil for Erectile Dysfunction
- PDE5 inhibitors (1/4): basic pharmacology, side effects, contraindications
- PDE5 inhibitors (2/4): Sildenafil
- PDE5 inhibitors (3/4): Tadalafil
- PDE5 inhibitors (4/4): Vardenafil
Review Literature: (Hatzimouratidis and Hatzichristou, 2007).
Basic pharmacology, side effects, drug interactions and contraindications of tadalafil please see section PDE5 inhibitors.
Indications for Tadalafil
Tadalafil is used for the medical treatment of erectile dysfunction.
Lower Urinary Tract Symptoms
Smooth muscle of the prostate and urinary bladder also express type 4 and type 5 phosphodiesterase. The release of NO relaxes the muscle cells and plays an important role during micturition. Randomized studies have shown that treatment with tadalafil relieves BPH symptoms (Laydner et al, 2011) (Oelke et al, 2012).
Pharmacokinetics of Tadalafil
- Good Absorption of tadalafil after oral administration: the maximum effective concentrations is reached after 2 h. Tadalafil can be taken with food, the maximum effective concentration is not changed.
- Degradation of tadalafil by hepatic cytochrome P450 (CYP3A4). Half-life 18 h. Excretion to 60% via the faeces.
Dosage of Tadalafil
In healthy men, the recommended starting dosage is 10 mg tadalafil. Depending on the effects and side effects, the dosage may then change to 20 mg tadalafil. In men with liver impairment, severe renal insufficiency, cardiac risk factors, in older men, with an antihypertensive medication or with cytochrome p450 inhibitors, the dosage should not be increased to 20 mg.
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
- Hatzimouratidis und Hatzichristou 2007 HATZIMOURATIDIS, Konstantinos ; HATZICHRISTOU, Dimitrios:
- Phosphodiesterase type 5 inhibitors: the day after.
In: Eur Urol
51 (2007), Jan, Nr. 1, S. 75–88; discussion 89
- Laydner, H. K.; Oliveira, P.; Oliveira, C. R. A.; Makarawo, T. P.; Andrade, W. S.; Tannus, M. & Araújo, J. L. R.
- Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. BJU Int, 2011, 107, 1104-1109.
- Oelke, M.; Giuliano, F.; Mirone, V.; Xu, L.; Cox, D. & Viktrup, L.
- Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol, 2012, 61, 917-925.
Deutsche Version: Tadalafil